JAMA Neurol:30年长期随访研究结果表明1/3的癫痫患者症状未有效控制

2017-12-28 zhangfan MedSci原创

尽管新作用机制的抗癫痫药物不断涌现,但新发癫痫患者的疾病控制效果仍不令人满意。大部分患者服用第一二代药物即可实现症状控制,但后续治疗的症状控制效果持续降低。超过1/3的癫痫患者症状仍未有效控制

2000年的研究发现,全球约1/3的癫痫患者接受药物治疗后症状未有效得到控制。近日研究人员对过去30年间10多个新批准抗癫痫药物的临床疗效进行了评估。

本次纵向观察队列研究在苏格兰开展。1982-2012年间,1795名新确诊癫痫患者接受抗癫痫药物治疗,研究随访期至少2年。研究的主要终点是癫痫症状的控制情况,考察新近批准的抗癫痫药物治疗后1年无症状率。采用多因素模型考察复发风险与治疗之间的关系。

1795名患者中,男性占53.7%,平均年龄33岁。研究结束时,1144名患者(63.7%)实现1年或以上无癫痫发作。无发作人群中,993人(86.8%)接受单一治疗,1028人(89.9%)接受第一代或二代抗癫痫药物。1年及以上无复发人群中,906人(50.5%)使用初始治疗方案。若初始治疗失败,使用第二三代抗癫痫药物的响应率分别提高11.6%和4.4%,仅2.21%的患者使用后续抗癫痫治疗后实现症状的有效控制。第一代抗癫痫药物未能实现疾病控制的患者,后续治疗失败的风险增加1.73倍(OR,1.73;95% CI,1.56-1.91; P<0.001)。

尽管新作用机制的抗癫痫药物不断涌现,但新发癫痫患者的疾病控制效果仍不令人满意。大部分患者服用第一二代药物即可实现症状控制,但后续治疗的症状控制效果持续降低。超过1/3的癫痫患者症状仍未有效控制。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2009214, encodeId=11722009214a8, content=<a href='/topic/show?id=1a35e15712e' target=_blank style='color:#2F92EE;'>#癫痫患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71571, encryptionId=1a35e15712e, topicName=癫痫患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 17 16:24:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967205, encodeId=27e8196e205fb, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Jan 09 02:24:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000239, encodeId=3ff420002392a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Apr 24 08:24:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716533, encodeId=600e1e16533e4, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sat Dec 30 22:24:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739478, encodeId=7ebe1e3947821, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Feb 04 06:24:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273835, encodeId=9e982e383550, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat Dec 30 10:58:21 CST 2017, time=2017-12-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2009214, encodeId=11722009214a8, content=<a href='/topic/show?id=1a35e15712e' target=_blank style='color:#2F92EE;'>#癫痫患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71571, encryptionId=1a35e15712e, topicName=癫痫患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 17 16:24:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967205, encodeId=27e8196e205fb, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Jan 09 02:24:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000239, encodeId=3ff420002392a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Apr 24 08:24:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716533, encodeId=600e1e16533e4, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sat Dec 30 22:24:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739478, encodeId=7ebe1e3947821, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Feb 04 06:24:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273835, encodeId=9e982e383550, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat Dec 30 10:58:21 CST 2017, time=2017-12-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2009214, encodeId=11722009214a8, content=<a href='/topic/show?id=1a35e15712e' target=_blank style='color:#2F92EE;'>#癫痫患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71571, encryptionId=1a35e15712e, topicName=癫痫患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 17 16:24:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967205, encodeId=27e8196e205fb, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Jan 09 02:24:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000239, encodeId=3ff420002392a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Apr 24 08:24:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716533, encodeId=600e1e16533e4, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sat Dec 30 22:24:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739478, encodeId=7ebe1e3947821, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Feb 04 06:24:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273835, encodeId=9e982e383550, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat Dec 30 10:58:21 CST 2017, time=2017-12-30, status=1, ipAttribution=)]
    2018-04-24 yinhl1978
  4. [GetPortalCommentsPageByObjectIdResponse(id=2009214, encodeId=11722009214a8, content=<a href='/topic/show?id=1a35e15712e' target=_blank style='color:#2F92EE;'>#癫痫患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71571, encryptionId=1a35e15712e, topicName=癫痫患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 17 16:24:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967205, encodeId=27e8196e205fb, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Jan 09 02:24:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000239, encodeId=3ff420002392a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Apr 24 08:24:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716533, encodeId=600e1e16533e4, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sat Dec 30 22:24:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739478, encodeId=7ebe1e3947821, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Feb 04 06:24:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273835, encodeId=9e982e383550, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat Dec 30 10:58:21 CST 2017, time=2017-12-30, status=1, ipAttribution=)]
    2017-12-30 habb
  5. [GetPortalCommentsPageByObjectIdResponse(id=2009214, encodeId=11722009214a8, content=<a href='/topic/show?id=1a35e15712e' target=_blank style='color:#2F92EE;'>#癫痫患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71571, encryptionId=1a35e15712e, topicName=癫痫患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 17 16:24:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967205, encodeId=27e8196e205fb, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Jan 09 02:24:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000239, encodeId=3ff420002392a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Apr 24 08:24:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716533, encodeId=600e1e16533e4, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sat Dec 30 22:24:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739478, encodeId=7ebe1e3947821, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Feb 04 06:24:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273835, encodeId=9e982e383550, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat Dec 30 10:58:21 CST 2017, time=2017-12-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2009214, encodeId=11722009214a8, content=<a href='/topic/show?id=1a35e15712e' target=_blank style='color:#2F92EE;'>#癫痫患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71571, encryptionId=1a35e15712e, topicName=癫痫患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 17 16:24:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967205, encodeId=27e8196e205fb, content=<a href='/topic/show?id=87729e0451f' target=_blank style='color:#2F92EE;'>#长期随访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97045, encryptionId=87729e0451f, topicName=长期随访)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Tue Jan 09 02:24:00 CST 2018, time=2018-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000239, encodeId=3ff420002392a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Apr 24 08:24:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716533, encodeId=600e1e16533e4, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Sat Dec 30 22:24:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739478, encodeId=7ebe1e3947821, content=<a href='/topic/show?id=8041e343504' target=_blank style='color:#2F92EE;'>#研究结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73435, encryptionId=8041e343504, topicName=研究结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbcd34536678, createdName=1249894fm84暂无昵称, createdTime=Sun Feb 04 06:24:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273835, encodeId=9e982e383550, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat Dec 30 10:58:21 CST 2017, time=2017-12-30, status=1, ipAttribution=)]
    2017-12-30 神功盖世

    学习

    0

相关资讯

讲真,睡得不好,这可能跟癫痫有关系…

1997年12月,日本任天堂播放的“皮卡丘”,由于使用了强烈的闪光效果和急剧变化的红蓝白三色刺激,导致很多儿童集体癫痫发作,当晚有共近700名儿童因癫痫发作被送进医院,“皮卡丘”也因此被禁播了6个月。这种由强烈的SSVEP导致的癫痫在学术上被称为光敏感性癫痫,也有人戏称为任天堂癫痫。

Neurology:KCNT1相关严重早发性癫痫的临床和分子特征

功能获得性KCNT1致病性突变可导致婴儿早发性严重局灶性癫痫,疾病机理研究表明奎尼丁对疾病具有潜在的治疗作用

Ann Neurol:胚胎神经节隆起祖细胞移植有望治疗药物抵抗性癫痫

研究认为,胚胎神经节隆起祖细胞移植可增加GABA介导的神经抑制功能,降低自发性癫痫的发作频率,缓解慢性癫痫动物模型的行为障碍

JAMA Neurol: 孕期叶酸补充可降低癫痫药物治疗母亲后代自闭风险

孕期叶酸补充可降低癫痫药物治疗母亲后代的自闭风险,对于接受抗癫痫药物治疗的孕产妇持续的叶酸补充是必需的

N Engl J Med:儿童和青少年耐药性癫痫的治疗:手术vs药物

2017年发表在《N Engl J Med》上的一项单中心试验,对改善儿童和青少年耐药性癫痫的发作中的脑手术+合理的药物治疗和仅接受药物治疗进行了分析比较。

儿童特发性全面性癫痫的诊疗挑战与对策

特发性全面性癫痫(IGEs)是儿童期至成年早期常见的具有遗传背景的全面性癫痫,发作类型以失神、肌阵挛及全面性强直阵挛发作为主。